Login to Your Account

Earnings Roundup

Gilead's HCV Data Eclipse Fourth-Quarter Earnings Miss

By Jennifer Boggs
Managing Editor

Monday, February 6, 2012

Gilead Sciences Inc.'s fourth-quarter earnings fell short of expectations, but the Foster City, Calif.-based firm's stock jumped Friday on promising early data from newly acquired hepatitis C virus (HCV) drug GS-7977.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription